ImPact Biotech Announces Research Collaboration to develop a treatment to arrest Pathologic Myopia using its Padeliporfin minimally invasive platform ImPact Biotech to collaborate with Maastricht University researchers to develop a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and...

ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) --  ImPact Biotech,...

ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer Designation confers advantages including marketing exclusivity and tax credits Padeliporfin VTP Phase 1 trial in Pancreatic cancer to start by end Q4 2023 TEL AVIV, Israel, July 05, 2023 (GLOBE...